Today: 11 November 2025
Subscribe
Browse Category

NYSE:AZN News 27 June 2025 - 6 November 2025

London Stock Exchange at Record Highs – Inside the Historic Market’s Brexit Battle and 2025 Revival

UK stocks today (6 Nov 2025): FTSE 100 edges lower before BoE decision; Sainsbury lifts profit guidance, ITV warns on Q4 ads, AstraZeneca beats

LONDON — Thursday, 6 November 2025 At a glance Market snapshot: waiting on Threadneedle Street UK equities were fractionally lower by late morning, with traders staying cautious ahead of the Bank of England’s midday decision and press conference. The FTSE 100 drifted as much as about 0.3%, while sterling hovered near recent lows against major peers amid growth concerns and budget uncertainty later this month. Reuters+1 Fresh data reinforced the slowdown narrative: the S&P Global/CIPS Construction PMI fell to 44.1 in October (from 46.2), marking the fastest drop in activity since May 2020 and the longest downturn since the financial
6 November 2025
 ·  ·  ·  ·  ·  ·  · 
Nasdaq Rally Amid Tech Frenzy: Markets Brush Off Shutdown Fears in Late September 2025

U.S. Stock Market Today (Nov. 6, 2025): Futures Mixed as Jobless Claims & Productivity Loom; Tesla Pay Vote, Airbnb & DraftKings Earnings in Focus

Here’s your fast, fact‑checked brief on what matters before the bell in the U.S. today (Thursday, Nov. 6, 2025). 1) Overnight & pre‑market snapshot 2) Today’s U.S. economic calendar (all times ET) Why it matters: Claims set the tone for labor‑market momentum; productivity and labor‑costs feed the inflation outlook that informs the Fed’s rate‑cut path into year‑end. Reuters 3) Earnings to watch Before the open / morning: After the close / evening: 4) Stocks on the move before the bell 5) Big storylines shaping sentiment today Supreme Court scrutiny of Trump‑era tariff powers Justices signaled skepticism in Wednesday’s arguments over
6 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

Stocks to Buy Today (Nov 6, 2025): ARM, AppLovin, Qualcomm, Tesla, Snap, AstraZeneca, Airbnb & More

Published: November 6, 2025 — This article curates today’s biggest catalysts and the most interesting stocks to consider, with fresh data and sources. Not financial advice. Today’s Market Backdrop (Nov 6, 2025) The Most Interesting Stocks to Buy Today Below are 10 names with fresh catalysts on Thursday, November 6, 2025. For each, we summarize the why now, the key numbers from today’s news flow, and what to watch next. 1) Arm Holdings (ARM) — AI Royalty Flywheel + Upbeat Guide Why now: Arm posted another $1B+ quarter and guided above expectations as AI demand lifts both licensing and royalties
6 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) reuters.com. (Nasdaq closes on Oct 31 showed ~$63.99 reuters.com.) Over the past month CRSP has gained roughly 17% genengnews.com, boosted by recent data releases. For example, a 3-day rally in mid-Oct lifted CRSP ~5% after the SyNTase/CTX460 results were announced genengnews.com. Technical indicators are mixed: the 14-day RSI is ~50 (neutral) and the MACD is slightly negative investing.com. Shorter moving averages (5/10/20-day around $63–$63.8) are giving buy signals investing.com, but the
2 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

Key Facts: Indices Performance European markets closed the first day of the week with small gains. The pan‑European STOXX 600 edged up 0.18% to 555.53 aa.com.tr. Germany’s DAX 40 barely budged (+0.02%) to 23,745.06 aa.com.tr, while Britain’s FTSE 100 added 0.16% to 9,299.84 aa.com.tr. France’s CAC 40 rose 0.13% to 7,880.87. By contrast, Italy’s FTSE MIB and Spain’s IBEX 35 both fell about 0.22% on the day aa.com.tr. Across the Atlantic, U.S. stock futures were little changed, reflecting caution ahead of key U.S. developments. On Tuesday Sept. 30, markets opened cautiously. Euro Stoxx 50 futures were slightly lower (off ~0.07%)
30 September 2025
 ·  ·  ·  ·  ·  ·  ·  · 
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

Market Overview On Monday, Europe’s stock markets built on last week’s Fed-inspired optimism. Investors cheered a mix of corporate news and the prospect of more US rate cuts. Britain’s FTSE 100 climbed roughly 0.5%, putting it near record highs, and the STOXX 600 closed about +0.2% reuters.com. France’s CAC 40 and Germany’s DAX each gained a few tenths of a percent reuters.com. Major indices in Southern Europe also edged up (Spain’s IBEX 35 and Italy’s FTSE MIB were broadly flat or slightly positive). Across sectors, the strongest gains were in healthcare and tech, offsetting weakness in commodity-linked areas and automakers.
29 September 2025
 ·  ·  ·  ·  ·  · 
Tariffs Fail to Derail European Stock Rally as Markets Bounce Back

Tariffs Fail to Derail European Stock Rally as Markets Bounce Back

Market Recap: Relief Rally Ends a Volatile Week German DAX stock index graph displayed at the Frankfurt Stock Exchange. European markets rebounded off three-week lows heading into the weekend (Sept. 24, 2025) reuters.com reuters.com European stocks staged a broad relief rally at week’s end, erasing earlier losses from a volatile week. On Friday, September 26, the STOXX Europe 600 index climbed +0.8%, clawing its way back from three-week lows hit mid-week reuters.com. This late surge left the STOXX 600 essentially where it began the week – up a marginal +0.07% over the five sessions reuters.com. Major national indexes were all
27 September 2025
 ·  ·  ·  ·  ·  ·  · 
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Key facts (today) The U.S. stock market today — what moved prices 1) The data that mattered: PCE & spendingMarkets exhaled as the Fed’s preferred inflation gauge arrived exactly as expected: headline PCE +0.3% m/m (2.7% y/y), core +0.2% m/m (2.9% y/y). Treasury yields drifted lower, with the 10‑yr near 4.18% and the 2‑yr around 3.65%, signaling relief that there was no upside shock. Futures ticked higher on the print.  Reuters “This should give some reassurances on the inflation side,” said Doug Beath of Wells Fargo Investment Institute.  Reuters Consumer spending stayed solid in August, adding to this week’s Q2 GDP revision to 3.8%. The resilience complicates the Fed’s job (growth strong, inflation easing
26 September 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Key Facts German DAX index graph at the Frankfurt Stock Exchange, reflecting volatile mid-week trading reuters.com. Pan-European Overview: From Slump to Rebound European equities seesawed over the two days, buffeted by transatlantic trade tensions and shifting rate expectations. On Thursday Sept. 25, the STOXX Europe 600 index dropped 0.7%, touching levels not seen in three weeks reuters.com. Almost every major bourse closed in the red reuters.com as traders digested a slew of worrying signals: fresh U.S. trade investigations into high-tech imports, surprisingly robust U.S. economic data, and guarded comments from central bankers. By Friday Sept. 26, however, markets regained footing
26 September 2025
 ·  ·  ·  ·  ·  ·  · 
AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

In April 2025, Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation. The device pairs an immunohistochemistry stain for TROP2 with a digital pathology AI algorithm that runs in Roche’s Navify system to analyze NSCLC biopsy slides. The AI calculates a Normalized Membrane Ratio (NMR), the ratio of surface TROP2 to internal TROP2, to classify tumors as TROP2-positive or -negative. The Ventana TROP2 RxDx is a full diagnostic system, including Roche’s slide scanners, the Navify image management software, the Ventana TROP2 IHC kit, and the AI algorithm. A positive NMR score thresholds
17 July 2025
 ·  ·  ·  ·  ·  · 
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug WVE-006 showed proof-of-mechanism in humans in 2024, and multi-dose trial data are anticipated in 2025. In April 2025, the FDA approved Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for the rare skin disorder RDEB, with launch planned in Q3
27 June 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Go toTop